Eliem Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Eliem Therapeutics, Inc. | ||
| Date: March 28, 2024 | By: | /s/ Andrew Levin |
|---|---|---|
| Andrew Levin, M.D., Ph.D. | ||
| Executive Chairman of the Board of Directors | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Andrew Levin | Executive Chairman of the Board of Directors | March 28, 2024 |
| Andrew Levin, M.D., Ph.D. | (Principal Executive Officer and Principal Financial Officer) | |
| /s/ Emily Pimblett | Chief Accounting Officer | March 28, 2024 |
| Emily Pimblett | (Principal Accounting Officer) | |
| /s/ Judith Dunn | Director | March 28, 2024 |
| Judith Dunn, Ph.D. | ||
| /s/ Liam Ratcliffe | Director | March 28, 2024 |
| Liam Ratcliffe, M.D., Ph.D. | ||
| /s/ Adam Rosenberg | Director | March 28, 2024 |
| Adam Rosenberg | ||
| /s/ Simon Tate | Director | March 28, 2024 |
| Simon Tate | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.